Celgene strikes $100 million deal for option to buy cancer drug maker Acetylon
This article was originally published in Scrip
Celgene entered into a drug development collaboration paying $100 million for an option to buy its new partner, closely held Acetylon Pharmaceuticals, which is in the early stages of testing a therapy for multiple myeloma.
You may also be interested in...
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.